Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type

Overview of attention for article published in Frontiers in oncology, September 2024

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (76th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

So far, Altmetric has seen 7 X posts from 7 X users, with an upper bound of 10,265 followers.

RT @RobertoBuonaiu3: Insights on PARPi in adv HGSOC: efficacy independent of BRCA domain defects or mutation types. Numerically longer mPFS…

Does the type of BRCA domain defects influence PARPi efficacy in HGSOC advanced pts? The answer just published in @FrontOncology 🔥 Congrats @RobertoBuonaiu3 and @NeolaGiuseppe and all co-authors! https://t.co/ufVDVlWGXU

Kudos to @RobertoBuonaiu3 and all the coauthors for this original article! https://t.co/67fUGmYazw

RT @RobertoBuonaiu3: Insights on PARPi in adv HGSOC: efficacy independent of BRCA domain defects or mutation types. Numerically longer mPFS…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 3 additional X posts.